Výsledky vyhledávání

Akademický článek

Impact of positron emission tomography - computed tomography status on progression-free survival for relapsed follicular lymphoma patients undergoing autologous stem cell transplantation.

Autor: Eyre TA; Department of Haematology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford. toby.eyre@ouh.nhs.uk., Barrington SF; King's College London and Guy's and St Thomas' PET Centre, School of Biomedical Engineering and Imaging Sciences, King's College London, King's Health Partners, London., Okosun J; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London., Abamba C; BSBMTCT data registry, 5th Floor Tabard House, Talbot Yard, Guy's Hospital, Great Maze Pond, London., Pearce RM; BSBMTCT data registry, 5th Floor Tabard House, Talbot Yard, Guy's Hospital, Great Maze Pond, London., Lee J; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London., Carpenter B; Department of Haematology, University College London Hospitals 235 Euston Road, London., Crawley CR; Department of Haematology and Bone Marrow Transplantation, Addenbrookes Hospital, Cambridge., Bloor AJC; Department of Haematology, The Christie Hospital NHS Trust, Manchester., Gilleece M; Department of Haematology and Bone Marrow Transplantation, Leeds Teaching Hospitals NHS Trust, Leeds., Nicholson E; Department of Haematology and Bone Marrow Transplantation, Royal Marsden Hospital, London., Shah N; Department of Haematology, Norfolk and Norwich University Hospitals, Norwich., Orchard K; Department of Haematology and Bone Marrow Transplantation, Southampton University Hospitals, Southampton., Malladi R; Department of Haematology and Bone Marrow Transplantation, Addenbrookes Hospital, Cambridge., Townsend WM; Department of Haematology, University College London Hospitals 235 Euston Road, London.

Publikováno v: Haematologica [Haematologica] 2023 Mar 01; Vol. 108 (3), pp. 785-796. Date of Electronic Publication: 2023 Mar 01.

Zobrazit plný text záznamu

Report

Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation.

Autor: Ruggeri A; San Raffaele Scientific Institute, Hematology and Bone marrow Transplantation Unit, Milan, Italy; Cellular Therapy and Immunobiology Working Party of the EBMT, Leiden., De Wreede LC; Leiden University Medical Center, Leiden., Müller CR; Zentrales Knochenmarkspender-Register Deutschland, Ulm., Crivello P; Institute for Experimental Cellular Therapy, University Hospital Essen, Essen., Bonneville EF; Leiden University Medical Center, Leiden., Petersdorf EW; Fred Hutchinson Cancer Research Center, Seattle., Socié G; Hôpital St. Louis, Paris., Dubois V; Histocompatibility Laboratory, EFS Lyon., Niittyvuopio R; HUCH Comprehensive Cancer Center, Helsinki., Peräsaari J; Clinical Laboratory Services, Histocompatibility Testing, Finnish Red Cross Blood Service, Helsinki., Yakoub-Agha I; CHU de Lille, Lille., Cornelissen JJ; Erasmus MC Cancer Institute, Rotterdam., Wieten L; Transplantation Immunology, Maastricht University Medical Center, Maastricht., Gedde-Dahl T; Oslo University Hospital, Rikshospitalet, Oslo., Forcade E; CHU Bordeaux, Pessac., Crawley CR; Addenbrookes Hospital, Cambridge., Marsh SGE; Anthony Nolan Research Institute and UCL Cancer Institute, Royal Free Campus, London,., Gandemer V; Centre Hospitalier Universitaire de Rennes, Rennes., Tholouli E; Manchester Royal Infirmary, Manchester., Bulabois CE; CHU Grenoble Alpes - Université Grenoble Alpes, Grenoble., Huynh A; CHU - Institut Universitaire du Cancer Toulouse, Toulouse., Choi G; University Medical Center Groningen (UMCG), Groningen., Deconinck E; Hopital Jean Minjoz, Besancon., Itäla-Remes M; Turku University Hospital, Turku., Lenhoff S; Skanes University Hospital, Lund., Bengtsson M; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala., Johansson JE; Sahlgrenska University Hospital, Goeteborg., Van Gorkom G; University Hospital Maastricht, Maastricht., Hoogenboom JD; EBMT Leiden Study Unit, Leiden., Vago L; San Raffaele Scientific Institute, Hematology and Bone marrow Transplantation Unit, Milan, Italy; Cellular Therapy and Immunobiology Working Party of the EBMT, Leiden., Rocha V; Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31) of the Service of Hematology and Cell Therapy, Hospital das Clínicas da Faculdade de Medicina da USP, São Paulo, SP., Bonini C; San Raffaele Scientific Institute, Hematology and Bone marrow Transplantation Unit, Milan, Italy; Cellular Therapy and Immunobiology Working Party of the EBMT, Leiden., Chabannon C; Cellular Therapy and Immunobiology Working Party of the EBMT, Leiden, The Netherlands; Institut Paoli-Calmettes, Centre de Lutte Contre le Cancer; Centre d'Investigations Cliniques en Biothérapie, Université d'Aix-Marseille, Inserm CBT 1409, Marseille., Fleischhauer K; Cellular Therapy and Immunobiology Working Party of the EBMT, Leiden, The Netherlands; Institute for Experimental Cellular Therapy, University Hospital Essen, Essen. katharina.fleischhauer@uk-essen.de.

Publikováno v: Haematologica [Haematologica] 2023 Feb 01; Vol. 108 (2), pp. 645-652. Date of Electronic Publication: 2023 Feb 01.

Zobrazit plný text záznamu

Akademický článek

RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature.

Autor: Chapman MA; Department of Haematology, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, Addenbrookes Hospital, Cambridge, United Kingdom., Sive J; Department of Haemato-oncology, St. Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom., Ambrose J; Bill Lyons Informatics Centre, UCL Cancer Institute, University College London, London, United Kingdom., Roddie C; Department of Haematology, University College London Hospitals, London, United Kingdom., Counsell N; Cancer Research UK and UCL Cancer Trials Centre, London, United Kingdom., Lach A; Department of Haematology, UCL Cancer Institute, University College London, London, United Kingdom., Abbasian M; Department of Haematology, UCL Cancer Institute, University College London, London, United Kingdom., Popat R; Department of Haematology, University College London Hospitals, London, United Kingdom., Cavenagh JD; Department of Haemato-oncology, St. Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom., Oakervee H; Department of Haemato-oncology, St. Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom., Streetly MJ; Department of Haematology, Guys and St. Thomas' Hospital, London, United Kingdom., Schey S; Department of Haematology, Kings College Hospital, London, United Kingdom., Koh M; Department of Haematology, St. George's Hospital, London, United Kingdom., Willis F; Department of Haematology, St. George's Hospital, London, United Kingdom., Virchis AE; Department of Haematology, Royal Free London, Barnet and Chase Farm Hospitals, London, United Kingdom., Crowe J; Department of Haematology, Royal United Hospitals Bath, Bath, United Kingdom., Quinn MF; Department of Haematology, Belfast City Hospital, Belfast, United Kingdom., Cook G; Department of Haematology, St. James's University Hospital, Leeds, United Kingdom., Crawley CR; Department of Haematology, Addenbrookes Hospital, Cambridge, United Kingdom., Pratt G; Centre for Clinical Haematology, University Hospitals Birmingham, Birmingham, United Kingdom., Cook M; Centre for Clinical Haematology, University Hospitals Birmingham, Birmingham, United Kingdom., Braganza N; Cancer Research UK and UCL Cancer Trials Centre, London, United Kingdom., Adedayo T; Cancer Research UK and UCL Cancer Trials Centre, London, United Kingdom., Smith P; Cancer Research UK and UCL Cancer Trials Centre, London, United Kingdom., Clifton-Hadley L; Cancer Research UK and UCL Cancer Trials Centre, London, United Kingdom., Owen RG; Haematological Malignancy Diagnostic Service, St. James' University Hospital, Leeds, United Kingdom., Sonneveld P; Erasmus Medical Centre, Rotterdam, The Netherlands; and., Keats JJ; Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix, AZ., Herrero J; Bill Lyons Informatics Centre, UCL Cancer Institute, University College London, London, United Kingdom., Yong K; Department of Haematology, UCL Cancer Institute, University College London, London, United Kingdom.

Publikováno v: Blood [Blood] 2018 Nov 15; Vol. 132 (20), pp. 2154-2165. Date of Electronic Publication: 2018 Sep 04.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání